About this trial

Sleep plays a role in cognitive processes such as memory processing, attention processing, and overall cognitive function. In recent years, the bidirectional relationship between sleep loss and aging, as well as related neurodegenerative diseases, has garnered widespread attention. Sleep disorders are a typical clinical manifestation of neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease and are closely related to the progression of these diseases. However, current research has yet to fully elucidate the physiological responses to sleep loss across different ages and cognitive levels, as well as the association and molecular basis between sleep loss, aging, and neurodegenerative diseases. This study aims to comprehensively characterize the transcriptional and metabolic changes in peripheral blood under sleep loss in populations of different ages and cognitive levels using multi-omics approaches and to preliminarily explore the role of sleep loss in aging and AD.

Eligibility criteria

Qualifiers

Signed informed consent form;

Meet the inclusion criteria for each arms.

Disqualifiers

Failure to provide informed consent;

Inability to follow study procedures due to issues such as language barriers or cognitive impairment;

Regular use of medications that may alter the relationship between sleep and outcome variables (e.g., opioid medications, benzodiazepines, and Z drugs [non-benzodiazepine hypnotics]);

History of alcohol abuse, substance abuse, consciousness disorders, cerebrovascular disease, head injury, epilepsy, encephalitis, or other neurological disorders;

Trial design

Treatments tested in this trial

  • Sleep manipulation

Treatment groups

60 Participants
are divided into 3 treatment groups

Locations

1
The First Affiliated Hospital of Zhejiang University310000, HangzhouZhejiang, China

Sponsors and collaborators

First Affiliated Hospital of Zhejiang University

Lead sponsor